PubRank

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

Clinical Trial ID NCT01233687

PubWeight™ 14.32‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01233687

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012 1.71
2 Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012 1.45
3 Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res 2014 1.33
4 MET as a possible target for non-small-cell lung cancer. J Clin Oncol 2013 1.25
5 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
6 Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol 2013 1.03
7 Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res 2014 1.00
8 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
9 Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biol Ther 2013 0.82
10 Prognostic and predictive value of MET deregulation in non-small cell lung cancer. Ann Transl Med 2015 0.81
11 Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? J Cancer 2016 0.79
12 MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res 2012 0.78
13 Combined treatment with MET inhibitors and other therapies in lung cancer. Transl Lung Cancer Res 2012 0.75
14 Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. J Exp Pharmacol 2011 0.75
Next 100